Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| ALKERMES (NASDAQ: ALKS) | Delayed: 43.74 -0.44 (1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.18 | 52 Week High | $80.71 | |||
| Open | $44.15 | 52 Week Low | $27.14 | |||
| Day High | $44.15 | P/E | 336.46 | |||
| Day Low | $43.15 | EPS | $0.13 | |||
| Volume | 151,636 | |||||
